Alternate Name(s):
ANAFRANIL®
Classification:
Antidepressant
Indications:
- Treatment of depressive disorders when there is an inability to tolerate oral administration
Reconstitution and Stability:
- Available as a 25 mg/2 mL injection
- Diluted solutions stable 24 hrs at room temperature or refrigerated
Compatibility:
- Solutions Compatible: D5W, 0.9% NaCl
- Additives/Above Cassette Compatible: no information
- Y-site Compatible: no information
- Incompatible: hydrocortisone, sodium bicarbonate
Administration:
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
| SC | NO |
| IM | NO |
| IV Push |
NO |
| IV Intermittant Infusion | YES Usual dilution: 10 mg in 35-70 mL; larger doses in 125-500 mL Infusion time: 1.5-3 hours |
| IV Continuous Infusion | NO |
Dosage:
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
- Pediatric ORAL dose: 1-1.5 mg/kg/day PO ÷ Q8-12H.
Maximum: 3 mg/kg/day or 200 mg; whichever is smaller. - Adolescent ORAL dose: 20-30 mg PO daily
- Intravenous dose conversion: 1/2 oral dose
- Pediatric IV dose not established
- Adolescents have received up to 200-300 mg IV once daily
- Initial Adult intravenous dose: 50-75 mg IV (once) daily
- Decrease dose in hepatic or renal failure
- Taper to discontinue to avoid withdrawal symptoms
Potential hazards of parenteral administration:
- Irritation at injection site
Notes:
- Postural hypotension, sinus tachycardia, widening of QRS complex, bundle-branch block
- Nausea
- Drowsiness, confusion, agitation, dizziness, headache, tremors, convulsions, hallucinations